Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Expanding PluvictoⓇ development program to address significant
unmet need in earlier lines and stages of prostate cancer
INNOVATION
Our ongoing clinical development plan for PluvictoⓇ in prostate cancer
Prostate cancer incidence in US, in patients per year
Early
disease
Local PC
283k1
BCR
41k1
Under evaluation
Advanced
disease
nmCRPC
33k1
MHSPC
39k1
PSMAddition (mHSPC) | Primary completion 2024
Late
disease
mCRPC 1L
42k1
mCRPC 2L+
27k1
PC
prostate cancer. BCR biochemical recurrence. nmCRPC non-metastatic castration-resistant prostate cancer.
1. Source: Kantar 2023 US Prostate Cancer Incidence, as of 30-Jan-2023
15 Investor Relations | Q4 2022 Results
PSMAfore (pre-taxane) | Primary completion 2022
VISION (post-taxane) | US/EU approval 2022
mHSPC metastatic hormone-sensitive prostate cancer. mCRPC - metastatic castration-resistant prostate cancer.
✓ NOVARTIS | Reimagining MedicineView entire presentation